CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE

Paramita Chakraborty; Shikhar Mehrotra

doi:10.1016/j.it.2020.01.008

CD38: Modulating Histone Methyltransferase EZH2 Activity in SLE

Trends Immunol. 2020 Mar;41(3):187-189. doi: 10.1016/j.it.2020.01.008. Epub 2020 Feb 12.

Authors

Paramita Chakraborty¹, Shikhar Mehrotra²

Affiliations

¹ Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
² Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: mehrotr@musc.edu.

PMID: 32061543
DOI: 10.1016/j.it.2020.01.008

Abstract

To keep autoreactive T cells under control in SLE patients, immunosuppressive regimens are used, which can increase susceptibility to bacterial and viral infections. Recently, Katsuyama et al., demonstrated that the CD38/NAD/Sirtuin1/EZH2 axis reduces cytolytic CD8⁺ T cell function and might be targeted to overcome incidence of infections.

Keywords: CD38; EZH2; SLE; T cells; methylation.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD8-Positive T-Lymphocytes
Enhancer of Zeste Homolog 2 Protein / genetics
Humans
Infections*
Lupus Erythematosus, Systemic*
NAD
Sirtuin 1

Substances

NAD
EZH2 protein, human
Enhancer of Zeste Homolog 2 Protein
Sirtuin 1